» Articles » PMID: 8530071

Gene Structure and Chromosomal Localization of the Human HSD11K Gene Encoding the Kidney (type 2) Isozyme of 11 Beta-hydroxysteroid Dehydrogenase

Overview
Journal Genomics
Specialty Genetics
Date 1995 Sep 1
PMID 8530071
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

11 beta-Hydroxysteroid dehydrogenase (11 beta HSD) converts glucocorticoids to inactive products and is thus thought to confer specificity for aldosterone on the type I mineralocorticoid receptor in the kidney. Recent studies indicate the presence of at least two isozymes of 11 beta HSD. In vitro, the NAD(+)-dependent kidney (type 2) isozyme catalyzes 11 beta-dehydrogenase but not reductase reactions, whereas the NADP(+)-dependent liver (type 1) isozyme catalyzes both reactions. We have now characterized the human gene encoding kidney 11 beta HSD (HSD11K). A bacteriophage P1 clone was isolated after screening a human genomic library by hybridization with sheep HSD11K cDNA. The gene consists of 5 exons spread over 6 kb. The nucleotide binding domain lies in the first and the second exon, and the catalytic domain in the fourth exon. The 5' flanking sequences and first exon are GC-rich (80%), suggesting that the gene may be transcriptionally regulated by factors that recognize GC-rich sequences. Fluorescence in situ hybridization of metaphase chromosomes with a positive P1 clone localized the gene to chromosome 16q22. In contrast, the HSD11L (liver isozyme) gene is located on chromosome 1 and contains 6 exons; the coding sequences of these genes are only 21% identical. HSD11K is expressed at high levels in the placenta and kidney of midgestation human fetuses and at lower levels in lung and testes. Different transcriptional start sites are utilized in kidney and placenta. These data should be applicable to genetic analysis of the syndrome of apparent mineralocorticoid excess, which may represent a deficiency of 11 beta HSD.

Citing Articles

Type-2 11β-hydroxysteroid dehydrogenase promotes the metastasis of colorectal cancer via the Fgfbp1-AKT pathway.

Chen J, Liu Q, Du P, Ning D, Mo J, Zhu H Am J Cancer Res. 2020; 10(2):662-673.

PMID: 32195034 PMC: 7061758.


Mechanisms for establishment of the placental glucocorticoid barrier, a guard for life.

Zhu P, Wang W, Zuo R, Sun K Cell Mol Life Sci. 2018; 76(1):13-26.

PMID: 30225585 PMC: 11105584. DOI: 10.1007/s00018-018-2918-5.


Clinical, genetic, and structural basis of apparent mineralocorticoid excess due to 11β-hydroxysteroid dehydrogenase type 2 deficiency.

Yau M, Haider S, Khattab A, Ling C, Mathew M, Zaidi S Proc Natl Acad Sci U S A. 2017; 114(52):E11248-E11256.

PMID: 29229831 PMC: 5748222. DOI: 10.1073/pnas.1716621115.


Hydroxysteroid dehydrogenase HSD1L is localised to the pituitary-gonadal axis of primates.

Bird A, Greatorex S, Reser D, Lavery G, Cole T Endocr Connect. 2017; 6(7):489-499.

PMID: 28871060 PMC: 5592779. DOI: 10.1530/EC-17-0119.


Brain mineralocorticoid receptors in cognition and cardiovascular homeostasis.

Gomez-Sanchez E Steroids. 2014; 91:20-31.

PMID: 25173821 PMC: 4302001. DOI: 10.1016/j.steroids.2014.08.014.